Laserwelt has entered into an agreement to distribute Verisante Technology's non-invasive optical system, designed for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma.
Using Raman spectroscopy, the CE mark-approved Verisante Aura system scans 20 to 40 skin lesions rapidly and provides immediate results, thus improving patient outcomes and comfort.
Verisante president and CEO Thomas Braun said under the agreement, Laserwelt will distribute Aura and also support technical training and servicing in Germany, Austria and Liechtenstein.
Laserwelt owner and president Michael Landsberg said Germany is the only country that has a national skin cancer screening program for persons over 35 years of age.
"Given that Aura's clinical study results show the device can quickly and accurately assist in skin cancer diagnosis, we are confident of widespread market adoption," Landsberg added.
